Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashok Chaudhary

Cardiovascular Disease New Brunswick, NJ Medical Doctor

NPI 1407022460 CMS profile 972673

125 Paterson St Ste 6100, New Brunswick, NJ 08901

Open in the dashboard

General payments

$144,366

383 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashok Chaudhary of New Brunswick, NJ is reported in the CMS Open Payments database as having received $144,366 across 383 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45,454 98
2024 General $51,429 55
2023 General $2,233 36
2022 General $14,564 35
2021 General $9,297 22
2020 General $8,415 21
2019 General $12,974 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashok Chaudhary
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ashok Chaudhary were reported at $45,454. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ashok Chaudhary Cardiovascular Disease median Middle half National median
2019 $12,974 $450 $127–$1,392 $163
2020 $8,415 $242 $77–$751 $114
2021 $9,297 $335 $101–$1,037 $132
2022 $14,564 $395 $121–$1,211 $149
2023 $2,233 $443 $136–$1,283 $160
2024 $51,429 $450 $136–$1,323 $164
2025 $45,454 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $84,108 119 payments
  2. Biosense Webster, Inc. $35,201 45 payments
  3. Medical Device Business Services, Inc. $6,600 2 payments
  4. Abbott Laboratories $5,921 72 payments
  5. Medtronic Vascular, Inc. $3,693 30 payments
  6. Medtronic, Inc. $3,373 14 payments
  7. Boston Scientific Corporation $1,954 40 payments
  8. Abiomed $1,769 40 payments
  9. W. L. Gore & Associates, Inc. $1,314 7 payments
  10. Shockwave Medical, Inc $91 1 payment
  11. Other $343 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $109,097 29 payments
  2. Travel and Lodging $18,489 81 payments
  3. Food and Beverage $10,680 266 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,100 5 payments
  5. Honoraria $3,000 2 payments
Products named General payments · program years 2019–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $67,276 28 payments
  2. Carto 3 $41,730 44 payments
  3. Edwards SAPIEN 3 Transcatheter Heart Valve $14,122 72 payments
  4. COREVALVE EVOLUT R $3,276 11 payments
  5. CoreValve Evolut $3,269 28 payments
  6. AMPLATZER AMULET $2,433 22 payments
  7. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $1,500 1 payment
  8. Impella $1,355 29 payments
  9. GORE CARDIOFORM Septal Occluder $1,314 7 payments
  10. TRICLIP $1,074 9 payments
  11. Other $6,064 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

829

Median for Cardiology: 2,533

Drug cost

$198,496

Median for Cardiology: $485,213

Branded share of claims

35.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 107 $110,924
Entresto Sacubitril/Valsartan Brand 24 $29,338
Brilinta Ticagrelor Brand 47 $29,046
Jardiance Empagliflozin Brand 20 $21,398
Metoprolol Succinate Generic 135 $2,387
Atorvastatin Calcium Generic 117 $1,316
Rosuvastatin Calcium Generic 38 $1,094
Clopidogrel Clopidogrel Bisulfate Brand 70 $777
Carvedilol Generic 48 $516
Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide Brand 25 $331

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$138,113

Of which drugs: $534

Medicare patients

1,884

Average age 76

Services billed

3,286

893 women, 991 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Diabetes 54%
Heart failure 53%
Arthritis 51%
Atrial fibrillation 49%
Chronic kidney disease 44%
Depression 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, perflutren lipid microspheres, per ml Q9957 Office 17 22 $534

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $32
$32 — —
DEFINITY
  • Lantheus Medical Imaging, Inc. $19
$19 — 22
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

383 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record